Compare Trip.com Group Ltd (TCOM) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Trip.com Group Ltd vs TG Therapeutics Inc — how do they compare? Trip.com Group Ltd trades at $38.82 (market cap $23.75B), while TG Therapeutics Inc trades at $54.85 (market cap $8.16B). The key difference: Trip.com Group Ltd is far larger — about 2.9× TG Therapeutics Inc's market cap, and Trip.com Group Ltd pays a 0.42% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Trip.com Group Ltd for 79 Days and TG Therapeutics Inc for 16 Days on average.
| TCOM | TGTX | |
|---|---|---|
Market Cap | $23.75B | $8.16B |
Volume | 2,089,737 | 1,735,121 |
Sector | Consumer Cyclical | Health |
52-Week High | $78.96 | $59.06 |
52-Week Low | $37.96 | $26.94 |
Typical Hold Time | 79 Days | 16 Days |
Enterprise Value | $15.91B | $8.37B |
Dividend Yield | 0.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Trip.com Group (TCOM) trades at $38.89, up 2.1% with mixed technical signals showing bearish moving averages but oversold RSI conditions. The company demonstrates strong fundamentals with revenue growing from $20.0B in 2022 to $62.4B in 2025, maintaining robust 36.9% net margins. Recent Q2 2026 earnings beat expectations at $1.07 per share versus $0.98 estimate, though regulatory headwinds from Chinese antitrust actions create uncertainty.
The stock presents a compelling value opportunity with low P/E of 7.34 and significant 46% upside to consensus price target of $56.64, supported by 70% analyst buy ratings. However, regulatory pressure on pricing algorithms and geopolitical risks require careful monitoring given the bearish technical setup and recent price volatility.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Trip.com Group Ltd
Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 78% of sales from accommodation reservations and transportation ticketing in 2020. The rest of revenue comes from package tours and corporate travel. Prior to the pandemic in 2019, the company generated 25% of revenue from international business, which is important to its margin expansion. Most of sales come from websites and mobile platforms, while the rest come from call centers. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Toncheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.
Read more on TCOM →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
